Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNiki BioSolutions, Inc.

Niki BioSolutions, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.77 USD 0.08 ( 4.73%)
Last update at 2026-11-03T20:45:00Z
VOLUME
44853
Market Cap
4.13M

Momentum Score

…

Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.69
Low
1.80
High
52 Week Price Range
5.05
Low
25.90
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.69
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.15
ROE
-17.06%
Net Debt
-0.01M
ROCE
-12.89%
Diluted EPS TTM
-2.55

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1.38M -4.16M -4.34M -11.53M -27.11M
Minority interest 0.01M -0.11M 1.52M 1.73M -
Net income -1.36M -4.27M -2.83M -9.80M -25.05M
Selling general administrative 1.64M 1.46M 4.37M 7.87M 8.03M
Selling and marketing expenses - - 0.05M 0.10M -
Gross profit 0.00M -0.26M 0.01M 0.08M 0.08M
Reconciled depreciation 0.00M 0.31M 1.38M 1.56M -
Ebit - -4.01M -10.60M -11.53M -27.02M
Ebitda -1.82M -3.76M -9.48M -10.32M -25.83M
Depreciation and amortization - 0.26M 1.12M 1.21M 1.19M
Operating income -1.82M -3.80M -10.60M -17.51M -19.21M
Other operating expenses 1.82M 3.80M 11.03M 18.80M 20.75M
Interest expense 0.10M 0.15M 0.12M - 0.09M
Interest income - - - 0.15M -
Net interest income -0.10M -0.15M -0.12M 0.15M -
Total revenue 0.00M 0.00M 0.43M 1.30M 1.54M
Total operating expenses 1.82M 3.54M 10.61M 17.25M 19.29M
Cost of revenue 0.00M 0.26M 0.42M 1.22M 1.46M
Total other income expense net 0.44M -0.36M 6.26M 5.98M -7.91M
Net income from continuing ops -1.38M -4.16M -4.34M -11.53M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 18.69M 16.13M 20.64M 20.87M 21.91M
Intangible assets - - 0.15M 0.75M 0.88M
Other current assets 0.14M 0.08M 0.40M 3.67M 0.59M
Total liab 4.90M 4.35M 5.26M 13.03M 4.40M
Total stockholder equity 23.16M 21.13M 24.85M 15.71M 23.61M
Other current liab 1.15M 1.00M 1.97M 6.18M 3.98M
Common stock 0.00M 0.00M 0.00M 35.71M 35.64M
Capital stock 0.00M 0.00M 0.00M 35.71M -
Retained earnings -73.79M -72.43M -68.16M -65.34M -55.54M
Cash 3.45M 0.87M 2.01M 1.88M 8.13M
Total current liabilities 4.59M 4.34M 2.10M 12.50M 4.38M
Net debt -0.01M 2.48M 1.28M 4.97M -7.91M
Short term debt 3.44M 3.34M 0.13M 6.32M 0.40M
Short long term debt 3.42M 3.24M - 6.01M -
Short long term debt total 3.44M 3.35M 3.28M 6.85M 0.22M
Other stockholder equity 97.05M 93.47M 93.02M 45.31M 43.51M
Total current assets 3.59M 0.96M 2.48M 7.07M 12.69M
Long term investments 15.10M 15.10M 16.10M 9.74M -
Short term investments - - 0.00M 0.10M 0.24M
Net receivables - 0.00M 0.07M 1.39M 3.56M
Long term debt - - 3.06M 0.50M -
Inventory - - 0.00M 0.03M 0.04M
Accumulated other comprehensive income -0.09M 0.09M -0.01M 0.03M -0.00M
Non currrent assets other - 0.07M 0.07M 0.13M 0.15M
Non current assets total 15.10M 15.17M 18.16M 13.80M 9.22M
Capital lease obligations 0.02M 0.12M 0.22M 0.34M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 0.00M 0.09M 0.00M -
Total cashflows from investing activities - 0.06M 0.62M 2.44M 16.51M
Net borrowings 0.00M 0.00M 2.50M 6.45M -
Total cash from financing activities 4.42M 0.00M 4.09M 6.63M 2.78M
Net income -1.38M -4.16M -4.34M -11.53M -27.11M
Change in cash 2.58M -1.13M -3.01M -3.25M 4.64M
Begin period cash flow 0.87M 2.01M 5.01M 8.26M 3.63M
End period cash flow 3.45M 0.87M 2.01M 5.01M 8.26M
Total cash from operating activities -1.84M -1.19M -7.72M -12.32M -14.65M
Issuance of capital stock 5.07M 0.00M 1.58M 0.01M -
Depreciation 0.00M 0.31M 1.38M 1.56M 1.19M
Other cashflows from investing activities - 0.06M 0.53M 2.63M -3.35M
Change to inventory 0.00M 0.00M 0.01M 0.01M 0.00M
Change to account receivables 0.02M 0.33M 0.42M -0.17M -0.02M
Other cashflows from financing activities -0.65M - 0.02M 0.17M 0.82M
Capital expenditures 0.00M 0.00M 0.00M 0.19M 0.14M
Change in working capital -0.10M -0.21M 0.46M 1.40M 1.02M
Stock based compensation 0.00M 0.00M 1.27M 1.65M 1.68M
Other non cash items -0.36M 2.87M -6.49M -5.40M 0.61M
Free cash flow -1.84M -1.19M -7.73M -12.51M -14.79M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NIKI
Niki BioSolutions, Inc.		 0.08
4.73%		 1.77 - - 23.35 0.22 31.22 -0.45
NVO
Novo Nordisk A/S		 -0.24
0.61%		 40.20 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -21.28
3.85%		 531.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 12.10
1.26%		 973.36 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Niki BioSolutions, Inc.

Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.

116 Village Boulevard, Princeton, NJ, United States, 08540

609 951 2222

https://www.aptorumgroup.com

1

Name Title Year Born
Mr. Chung Yuen Huen Founder, Executive Chairman & CEO 1980
Mr. Kwok Kuen Wong Head of Finance 1956
Dr. Alidad Mireskandari M.B.A., Ph.D. President, COO & Board Observer 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…